Clinical Trials Logo

Clinical Trial Summary

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.


Clinical Trial Description

165-302 is a Phase 3, 4 Part, Randomized, Double-Blind, Placebo-Controlled, Discontinuation Study to Evaluate the Efficacy and Safety of Self Administered Subcutaneous Injections of BMN 165 by Adults With PKU. This study is open only to adults who have been exposed to BMN165 in a previous study. Study BMN 165-302 is a four-Part, Phase 3 study. - Part 1: Open-label period - Part 2: A Randomized, double-blind, placebo-controlled period of 8 weeks - Part 3: Two sub-Parts to Part 3:- Part 3A - BMN 165 administered using vial and syringe during this open label period. Part 3B - BMN 165 administered using prefilled syringe during this open-label period. - Part 4: A long-term, open-label extension period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01889862
Study type Interventional
Source BioMarin Pharmaceutical
Contact
Status Completed
Phase Phase 3
Start date July 29, 2013
Completion date February 5, 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04480567 - AAV Gene Therapy Study for Subjects With PKU Phase 1/Phase 2
Completed NCT03694353 - Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU Phase 3
Completed NCT04086511 - PANDA: PKU Amino Acid Evaluation
Completed NCT02440932 - Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis N/A
Completed NCT01617070 - Effects of Kuvan on Melatonin Secretion Phase 4
Completed NCT03505125 - A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
Terminated NCT01806051 - A Pilot Study on Diurnal Variation N/A
Recruiting NCT05813678 - A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
Active, not recruiting NCT05270837 - Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria Phase 3
Completed NCT02009904 - Simple Breath Test to Examine Phenylalanine Metabolism
Recruiting NCT06305234 - A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
Recruiting NCT03309345 - Body Composition, Energy Intake and Expenditure in People With Phenylketonuria N/A